TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9696082

Group type: COMPARATOR
Intervention: Standard differential-pressure valve
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Delta valve (Medtronic PS Medical)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Orbis-Sigma valve (Cordis)
Number of subjects: 344
Study: 7730892

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Summated MAI
Number of subjects: 208
Study: 2720725

Group type: EXPERIMENTAL
Intervention: Stuart Prenatal tablet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stuartnatal 1 + 1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Materna 1.60
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stuartnatal 1 + 1 and Materna 1.60
Number of subjects: 17
Study: 29027602

Group type: EXPERIMENTAL
Intervention: Risk reduction information present
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Risk reduction information absent
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: No social comparison information
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Social comparison information present (higher than average risk)
Number of subjects: 1161
Study: 29070027

Group type: EXPERIMENTAL
Intervention: Aerobic cycling exercise at 70% of the heart rate reserve [0.7 × (HRmax - HRrest)]
Number of subjects: 22
Study: 26328782

Group type: EXPERIMENTAL
Intervention: Fish oil-EE (ethyl ester)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fish oil-TG (triglyceride)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 66

Group type: COMPARATOR
Intervention: All groups (Fish oil-EE, Fish oil-TG, Krill oil)
Number of subjects: 66
Study: 23211514

Group type: EXPERIMENTAL
Intervention: Mixed-nutrient drink (500 ml, 532 kcal)
Number of subjects: 60
Study: 21998288

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Bacteroides fragilis
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Bacteroides thetaiotaomicron
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Clostridium species
Number of subjects: 1209
Study: 18086493

Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation (single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.6 mg racemic albuterol after fluticasone pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albuterol formulations after placebo or fluticasone pretreatment
Number of subjects: 20
Study: 16130018

Group type: EXPERIMENTAL
Intervention: Functional electrical therapy (N=12)
Number of subjects: 21
Study: 14574751

Group type: EXPERIMENTAL
Intervention: Printed test
Number of subjects: 210

Group type: COMPARATOR
Intervention: Computerized test
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Number of subjects: 210
Study: 10668942

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8674162

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (250, 500, 750, 1000, 1200 mg/m2) infused over 2 hours on days 1 and 2, with G-CSF 5 micrograms/kg per day starting on day 3 until WBC was > or = 10,000/microliters
Number of subjects: 21
Study: 1898644

Group type: EXPERIMENTAL
Intervention: Surgery plus medical treatment
Number of subjects: 468

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 468
Study: 6344715

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide plus low-dose prednisone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral azathioprine plus low-dose prednisone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 53
Study: 30794084

Group type: EXPERIMENTAL
Intervention: TRT+RT (Testosterone Replacement Therapy + Resistance Training)
Number of subjects: 22

Group type: COMPARATOR
Intervention: TRT (Testosterone Replacement Therapy)
Number of subjects: 22
Study: 28640845

Group type: COMPARATOR
Intervention: Instruction-only group (n = 262; issued with pre-scripted instructions on the low-sensitivity pregnancy test)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Demonstration group (n = 263; performed practice tests guided by lay health workers)
Number of subjects: 525
Study: 26896232

Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) with sequential introduction of 6 allergenic foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), and wheat; continued breastfeeding.
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Standard introduction group following UK infant feeding recommendations of exclusive breastfeeding for around 6 months with no introduction of allergenic foods before 6 months of age.
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG)
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1303
Study: 25142305

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000mg daily)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 932
Study: 22581994

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² intravenously) as add-on therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Prednisone and calcineurin inhibitors (standard treatment)
Number of subjects: 31
Study: 19339061

Group type: EXPERIMENTAL
Intervention: Factors associated with allergic rhinitis
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Carpets
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Air pollution
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Other factors (low birth weight, maternal age, parental education, gestational complications, tobacco smokers, pets, molds)
Number of subjects: 1368
Study: 17445857

Group type: EXPERIMENTAL
Intervention: Two concurrent moving stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flash stimuli
Number of subjects: 0
Study: 16087005

Group type: COMPARATOR
Intervention: Sandblasting (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laser etching at 3.0 J/cm2 (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laser etching at 4.0 J/cm2 (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laser etching at 4.9 J/cm2 (Group IV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of sandblasting and laser etching at 4.0 J/cm2 (Group V)
Number of subjects: 40
Study: 12106575

Group type: EXPERIMENTAL
Intervention: Health education programme consisting of four sessions
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study: 10798126

Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation 1.0 x 10(8) million viable spores/day/child for 15 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation 2.0 x 10(8) million viable spores/day/child for 90 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30
Study: 7747375

Group type: COMPARATOR
Intervention: Isotretinoin 1 mg/kg orally daily until remission (max 3 months)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a 3 x 10(5) IU subcutaneously three times weekly plus isotretinoin 1 mg/kg orally daily until remission (max 8 weeks)
Number of subjects: 86
Study: 2103760

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg t.d.s.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7339223

Group type: COMPARATOR
Intervention: Continuous training at a heart rate of 140 b/min (C140)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous training at a heart rate of 172 b/min (C172)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interval training at a heart rate of 140 b/min (I140)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interval training at a heart rate of 172 b/min (I172)
Number of subjects: 24
Study: 31950481

Group type: EXPERIMENTAL
Intervention: Iloprost (1 ng/kg/min)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo (equal volume of saline)
Number of subjects: 384
Study: 29910795

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with concomitant chemoradiotherapy (CCRT) with temozolomide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional treatment without immunotherapy
Number of subjects: 47
Study: 26750130

Group type: EXPERIMENTAL
Intervention: PCV (procarbazine, CCNU, vincristine) chemotherapy following radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 24625530

Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 21963319

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation of tibia at 0.3g, 0.6g, and 1.2g at 30Hz
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation of tibia
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Single bout of mechanical oscillation
Number of subjects: 11
Study: 20677726

Group type: EXPERIMENTAL
Intervention: 90 microm flap thickness
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 100 microm flap thickness
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 110 microm flap thickness
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 120 microm flap thickness
Number of subjects: 240
Study: 18386581

Group type: EXPERIMENTAL
Intervention: TCM therapy combined with radiotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 55
Study: 15989938

Group type: COMPARATOR
Intervention: Left TLE patients
Number of subjects: 124

Group type: COMPARATOR
Intervention: Left TLE patients with lateral temporal lobe lesions
Number of subjects: 124

Group type: COMPARATOR
Intervention: Left TLE patients with mesial temporal lobe lesions
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Episodic memory factor
Number of subjects: 124
Study: 12602446

Group type: EXPERIMENTAL
Intervention: 180 mg fexofenadine (F)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 50 mg diphenhydramine (D)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study: 10982197

Group type: EXPERIMENTAL
Intervention: Slow-release melatonin, 2 mg/day for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study: 8828240

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (6 sessions) in addition to usual methadone maintenance treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual methadone maintenance treatment only
Number of subjects: 80
Study: 1349509

Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine once daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 25 mg of hydroxyzine thrice daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo thrice daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Somnolence or sedation
Number of subjects: 59
Study: 3882583

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate sustained-release tablets
Number of subjects: 28
Study: 3521531

Group type: EXPERIMENTAL
Intervention: Thiothixene (Navane)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30336580

Group type: EXPERIMENTAL
Intervention: Low glycaemic index carbohydrate diet replacing saturated fatty acids (SFA)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) and high glycaemic index carbohydrates replacing saturated fatty acids (SFA)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) and low glycaemic index carbohydrates replacing saturated fatty acids (SFA)
Number of subjects: 389
Study: 27072189

Group type: EXPERIMENTAL
Intervention: SMS prompts
Number of subjects: 56

Group type: COMPARATOR
Intervention: Historical control (no SMS prompts)
Number of subjects: 56
Study: 24642828

Group type: EXPERIMENTAL
Intervention: 20% mannitol (5 mL/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3% hypertonic saline (5 mL/kg)
Number of subjects: 50
Study: 22613428

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) plus patient-controlled analgesia (PCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus patient-controlled analgesia (PCA)
Number of subjects: 60
Study: 20128535

Group type: EXPERIMENTAL
Intervention: Bilateral AcrySof ReSTOR Natural (SN60D3) intraocular lens (IOL) implantation
Number of subjects: 23
Study: 18843564

Group type: EXPERIMENTAL
Intervention: Health intervention programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control programme with aesthetic content
Number of subjects: 82
Study: 16394436

Group type: EXPERIMENTAL
Intervention: Oral itraconazole 100 mg, two capsules twice daily for seven days a month for four months.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral terbinafine 250 mg, one tablet twice daily for seven days every month for four months.
Number of subjects: 120
Study: 12927462

Group type: EXPERIMENTAL
Intervention: Inner fibre framework (sandblasted and silane coated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inner composite layer (sandblasted and silane coated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (inner fibre framework, not sandblasted or silane coated)
Number of subjects: 0
Study: 11218052

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study: 8881809

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 47
Study: 1404052

Group type: EXPERIMENTAL
Intervention: All dressings discarded after 5 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Occlusive bandage continued for a further 2 weeks
Number of subjects: 33
Study: 4009554

Group type: EXPERIMENTAL
Intervention: Prenatal supplement with reduced amounts of calcium and magnesium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two other prenatal supplements
Number of subjects: 0
Study: 30156758

Group type: EXPERIMENTAL
Intervention: ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: ABBV-257 (various doses: 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ABBV-257 (single-dose study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ABBV-257 (multiple-dose study)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ABBV-257
Number of subjects: 48
Study: 30351407

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors (RASi)
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Non-renin-angiotensin system inhibitors (non-RASi)
Number of subjects: 2416
Study: 27456597

Group type: EXPERIMENTAL
Intervention: Microcrystalline cellulose nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24720640

Group type: EXPERIMENTAL
Intervention: Pouch technique combined with connective tissue graft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coronally advanced flap combined with connective tissue graft
Number of subjects: 40
Study: 22749223

Group type: EXPERIMENTAL
Intervention: Progesterone support stopped at week 5
Number of subjects: 220

Group type: COMPARATOR
Intervention: Progesterone support stopped at week 8
Number of subjects: 220
Study: 20656210

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline cognitive function assessment
Number of subjects: 32
Study: 17388220

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride 180 mg once daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 15622228

Group type: EXPERIMENTAL
Intervention: Intraoral camera method
Number of subjects: 13

Group type: COMPARATOR
Intervention: Graph paper method
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison of methods
Number of subjects: 13
Study: 12187210

Group type: EXPERIMENTAL
Intervention: Orchiectomy and placebo
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Orchiectomy and flutamide
Number of subjects: 1286
Study: 10795758

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous) during normoglycemia (5-8.9 mmol/liter glucose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous) during hyperglycemia (16-19 mmol/liter glucose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo during normoglycemia (5-8.9 mmol/liter glucose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo during hyperglycemia (16-19 mmol/liter glucose)
Number of subjects: 14
Study: 8632217

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 1485474

Group type: EXPERIMENTAL
Intervention: 400 mg dipyridamole per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 4048888

Group type: EXPERIMENTAL
Intervention: Autologous centrifuged blood
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Washed, packed red blood cells
Number of subjects: 20
Study: 29265672

Group type: EXPERIMENTAL
Intervention: Hand in Hand (HiH) intervention in addition to usual care
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 198
Study: 28363932

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire, Distress Thermometer Analogue Scale and PSYCHLOPS problem profile for monitoring depression, feedback of scores to patients by practitioners.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire, Distress Thermometer Analogue Scale and PSYCHLOPS problem profile for monitoring depression.
Number of subjects: 47
Study: 26232060

Group type: EXPERIMENTAL
Intervention: Multicomponent Mental Competency and Stress Management Training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 21704392

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2708
Study: 20840208

Group type: EXPERIMENTAL
Intervention: Community-based prevention programme
Number of subjects: 123235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123235
Study: 18812486

Group type: EXPERIMENTAL
Intervention: Oral DHEA 50 mg/d for 12 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 16480006

Group type: EXPERIMENTAL
Intervention: Mechanical valve (Medtronic Hall or Medtronic ADVANTAGE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biological valve (Medtronic Mosaic or Medtronic Freestyle)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle stentless valve
Number of subjects: 40
Study: 12928584

Group type: EXPERIMENTAL
Intervention: 1% isoflurane concentration (C(I)iso)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2% isoflurane concentration (C(I)iso)
Number of subjects: 16
Study: 10633020

Group type: COMPARATOR
Intervention: Protemp II (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Luxatemp, Provipont, or Triad‐VLC (experimental)
Number of subjects: 30
Study: 9122311

Group type: EXPERIMENTAL
Intervention: CFS patients (depressed)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CFS patients (non-depressed)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CFS patients (both groups)
Number of subjects: 3
Study: 8393272

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (group A) including 60 mg/m2 of cisplatin (CDDP), 13 mg/m2 of Adriamycin (ADM), 150 mg of 5‐fluorouracil (5‐FU), Tamoxifen (TAM) 25 mg/m2 daily, and medroxyprogesterone acetate (MPA) 400 mg/m2 daily, administered orally and alternated every 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group B) receiving the same anticancer drugs without hormonal agents
Number of subjects: 30
Study: 3737905

Group type: EXPERIMENTAL
Intervention: Multiplanar reconstruction (MPR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard transaxial imaging
Number of subjects: 30
Study: 29161531

Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 25 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 50 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 35 mg (weeks 1-2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 50 mg (weeks 3-4)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 28009467

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) for 10 weeks, including six online therapy lessons with content summaries and homework assignments
Number of subjects: 77

Group type: COMPARATOR
Intervention: Monitored attention control (MAC) for 10 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Monitored attention control (MAC)
Number of subjects: 77
Study: 25627338

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg (based on escape status)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 22981787

Group type: EXPERIMENTAL
Intervention: Cat-PAD (6-nmol dose, 4 administrations, 4 weeks apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cat-PAD (3-nmol dose, 8 administrations, 2 weeks apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0